321 related articles for article (PubMed ID: 19343229)
1. Eltrombopag in chronic idiopathic thrombocytopenic purpura and HCV-related thrombocytopenia.
Panzer S
Drugs Today (Barc); 2009 Feb; 45(2):93-9. PubMed ID: 19343229
[TBL] [Abstract][Full Text] [Related]
2. Eltrombopag: an oral thrombopoietin receptor agonist for the treatment of idiopathic thrombocytopenic purpura.
Zhang Y; Kolesar JM
Clin Ther; 2011 Nov; 33(11):1560-76. PubMed ID: 22054810
[TBL] [Abstract][Full Text] [Related]
3. Eltrombopag for treatment of thrombocytopenia-associated disorders.
Merli P; Strocchio L; Vinti L; Palumbo G; Locatelli F
Expert Opin Pharmacother; 2015; 16(14):2243-56. PubMed ID: 26364898
[TBL] [Abstract][Full Text] [Related]
4. Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia.
Garnock-Jones KP
BioDrugs; 2011 Dec; 25(6):401-4. PubMed ID: 22050343
[TBL] [Abstract][Full Text] [Related]
5. Eltrombopag--an oral thrombopoietin agonist.
Sharma V; Randhawa H; Sharma A; Aggarwal S
Eur Rev Med Pharmacol Sci; 2012 Jun; 16(6):743-6. PubMed ID: 22913204
[TBL] [Abstract][Full Text] [Related]
6. Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.
Kühne T; Imbach P
Ann Hematol; 2010 Jul; 89 Suppl 1():67-74. PubMed ID: 20405290
[TBL] [Abstract][Full Text] [Related]
7. Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia.
Garnock-Jones KP
Drugs; 2011 Jul; 71(10):1333-53. PubMed ID: 21770480
[TBL] [Abstract][Full Text] [Related]
8. Eltrombopag: A Review in Paediatric Chronic Immune Thrombocytopenia.
Burness CB; Keating GM; Garnock-Jones KP
Drugs; 2016 May; 76(8):869-78. PubMed ID: 27151255
[TBL] [Abstract][Full Text] [Related]
9. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura.
Stasi R; Evangelista ML; Amadori S
Drugs; 2008; 68(7):901-12. PubMed ID: 18457458
[TBL] [Abstract][Full Text] [Related]
10. Infection-related transient loss of response and other early side effects in chronic ITP during treatment with thrombopoietin mimetics.
Meyer O; Salama A
Onkologie; 2011; 34(1-2):10-3. PubMed ID: 21346379
[TBL] [Abstract][Full Text] [Related]
11. Eltrombopag. Idiopathic thrombocytopenic purpura after treatment failure: romiplostim is a better option.
Prescrire Int; 2010 Feb; 19(105):15. PubMed ID: 20455333
[TBL] [Abstract][Full Text] [Related]
12. Dental procedures in 24 patients with chronic immune thrombocytopenia in prospective clinical studies of eltrombopag.
Tarantino MD; Fogarty PF; Shah P; Brainsky A
Platelets; 2015; 26(1):93-6. PubMed ID: 24433306
[TBL] [Abstract][Full Text] [Related]
13. Moving towards a new era in the management of chronic immune thrombocytopenia.
Wadenvik H; Olsson B
Ann Hematol; 2010 Jul; 89 Suppl 1():87-93. PubMed ID: 20339846
[TBL] [Abstract][Full Text] [Related]
14. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
[TBL] [Abstract][Full Text] [Related]
15. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim.
Kuter DJ; Macahilig C; Grotzinger KM; Poston SA; Wang PF; Dawson KL; Ward M
Int J Hematol; 2015 Mar; 101(3):255-63. PubMed ID: 25586660
[TBL] [Abstract][Full Text] [Related]
16. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
[TBL] [Abstract][Full Text] [Related]
17. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.
Bussel JB; Cheng G; Saleh MN; Psaila B; Kovaleva L; Meddeb B; Kloczko J; Hassani H; Mayer B; Stone NL; Arning M; Provan D; Jenkins JM
N Engl J Med; 2007 Nov; 357(22):2237-47. PubMed ID: 18046028
[TBL] [Abstract][Full Text] [Related]
18. Review article: second-generation thrombopoietin agents for treatment of chronic idiopathic thrombocytopenic purpura in adults.
Lam MS
J Oncol Pharm Pract; 2010 Jun; 16(2):89-103. PubMed ID: 19525300
[TBL] [Abstract][Full Text] [Related]
19. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.
Bussel JB; Provan D; Shamsi T; Cheng G; Psaila B; Kovaleva L; Salama A; Jenkins JM; Roychowdhury D; Mayer B; Stone N; Arning M
Lancet; 2009 Feb; 373(9664):641-8. PubMed ID: 19231632
[TBL] [Abstract][Full Text] [Related]
20. Eltrombopag--a novel approach for the treatment of chronic immune thrombocytopenic purpura: review and safety considerations.
Cook L; Cooper N
Drug Des Devel Ther; 2010 Jul; 4():139-45. PubMed ID: 20689640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
